Novozymes A/S (OTCMKTS:NVZMY) Short Interest Update

Novozymes A/S (OTCMKTS:NVZMY) was the recipient of a significant drop in short interest in the month of August. As of August 14th, there was short interest totaling 1,871 shares, a drop of 48.1% from the July 30th total of 3,603 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily volume of 38,102 shares, the days-to-cover ratio is currently 0.0 days.

Analysts Set New Price Targets

NVZMY has been the subject of several analyst reports. Kepler Capital Markets upgraded shares of Novozymes A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Zacks Research raised shares of Novozymes A/S from a “strong sell” rating to a “hold” rating in a report on Monday, June 8th. Two analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy”.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Novozymes A/S stock. Elefante Mark B boosted its position in Novozymes A/S (OTCMKTS:NVZMY) by 73.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,900 shares of the biotechnology company’s stock after buying an additional 2,500 shares during the quarter. Elefante Mark B’s holdings in Novozymes A/S were worth $371,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Novozymes A/S Stock Performance

Shares of NVZMY opened at $71.68 on Tuesday. The firm has a market cap of $29.71 billion, a P/E ratio of 45.37, a PEG ratio of 3.16 and a beta of 0.92. Novozymes A/S has a twelve month low of $49.90 and a twelve month high of $75.27. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.03 and a current ratio of 1.67. The firm’s 50 day moving average price is $65.36 and its two-hundred day moving average price is $61.10.

Novozymes A/S (OTCMKTS:NVZMY) last issued its quarterly earnings data on Thursday, August 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by ($0.16). The company had revenue of $1.30 billion for the quarter, compared to the consensus estimate of $1.27 billion. Novozymes A/S had a return on equity of 6.60% and a net margin of 14.70%. On average, analysts forecast that Novozymes A/S will post 2.47 EPS for the current fiscal year.

About Novozymes A/S

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).